[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"herpes-simplex\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:herpes-simplex":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100526419","phase-3-acyclovir-in-ventilated-patients-with-pneumonia-and-hsv-1-in-bal-100526419",false,"NCT06134492","Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL","Effect of Acyclovir Therapy on the Outcome of Ventilated Patients With Lower Respiratory Tract Infection and Detection of Herpes Simplex Virus in Bronchoalveolar Lavage","HerpMV","Inclusion Criteria:\n\n1. ≥ 18 years\n2. need for invasive or non-invasive respiratory support\n3. PCR HSV-1 detection in BAL (≥ 10\\^3 copies\u002Fml)\n4. Pneumonia (community or healthcare acquired, incl. ventilator-associated pneumonia)\n5. declaration of consent by the patient or legal representative\n\nExclusion Criteria:\n\n1. History of hypersensitivity to acyclovir or valacyclovir or other components of the investigational product.\n2. Pregnancy\u002FLactation\n3. Simultaneous participation in another interventional clinical trial\n4. Decision to withhold life-sustaining therapies\n5. Use of a virostatic agent (i.v. or p. os) with activity against herpes simplex (acyclovir, valacyclovir, famciclovir\u002Fpenciclovir, brivudine, cidofovir, foscarnet) for therapeutic or prophylactic reasons at the time of randomization.\n6. Solid organ transplantation, stem cell transplantation\n7. Neutropenia (absolute neutrophil count \\\u003C1500\u002Fμl (\\\u003C1.5 × 109 \u002Fl)\n8. Previous study participation in HerpMV","ALL","18 Years",{"count":20,"type":21},616,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Almost 90 out of 100 people carry herpes simplex viruses (HSV). Once a person has been infected with the herpes viruses, he or she can't get rid of them for the rest of her\u002Fhis life. For the most part, the viruses are in a dormant state. Only when the immune system is weakened, for example in the case of a serious illness or stress, are the viruses reactivated. They then mainly cause cold sores, which are harmless for healthy people and usually heal without therapy. However, especially in people with a weakened immune system, HSV can also cause serious infections, such as meningitis. In almost every second mechanically ventilated patient in intensive care who has pneumonia, HSV can be detected in the respiratory tract. This is caused by reactivation of the viruses as a result of the severe underlying disease and stress during intensive care therapy. Whether treatment of the herpes viruses (e.g. with acyclovir) is necessary in this situation and helps the patients to cure has not been clarified, especially as acyclovir can also cause side effects such as a deterioration in kidney function. Currently, the physicians decide to treat the herpes viruses in about half of the patients. Several studies have shown that patients for whom the physician decided to treat the viruses survived more often. However, all of these studies looked at the course of the disease only retrospectively and thus are subject to many biases (including physician selection of who receives treatment, missing data). A definitive conclusion as to whether herpesvirus therapy can be recommended cannot be drawn without doubt from these studies. Therefore, the investigators would like to investigate in a randomized controlled trial, i.e. patients are randomly assigned to the experimental (therapy of herpesviruses) or control group (no therapy of herpesviruses), the effect of therapy with acyclovir on survival in ventilated intensive care patients with lower respiratory tract infection (pneumonia) in whom a large amount of HSV was found in the respiratory tract. The goal of the study is to provide clarity on whether therapy will help patients recover.",[27,28,29,30,31],"Pneumonia, Viral","Ventilator Associated Pneumonia","Community-acquired Pneumonia","Herpes Simplex","Hospital-acquired Pneumonia",[33,30,34,35],"Pneumonia","Mechanical Ventilation","Aciclovir","RECRUITING","2025-11-18",{"date":39,"type":40},"2025-11-21","ACTUAL",{"date":42,"type":40},"2024-02-20",{"date":44,"type":21},"2026-12",{"name":46,"class":47},"Jena University Hospital","OTHER",28,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100367567","phase-4-randomized-placebo-controlled-double-blind-study-of-2lherp-in-orofacial-herpes-infections-100367567","NCT04065971","Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections.","Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy of 2LHERP® in Patients With Recurrent Orofacial Herpes Infections.","HEARTH-OF","Inclusion Criteria:\n\n* Man or woman aged 16-80 years,\n* Patient presenting 6 or more episodes of orofacial herpes infections during the preceding 12-months' period (prior to the study entry),\n* Woman of childbearing age under effective contraception,\n* Patient reporting a current stable sexual relationship (steady sexual partner during study duration),\n* Patient having faculties to understand and respect the constraints of the study,\n* Signature of the Informed Consent Form.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman,\n* Patient under immunotherapy (including immunosuppressive treatment) or micro-immunotherapy received during last previous 6 months,\n* Patient who had a suppressive antiviral therapy during last month,\n* Patient who wishes to continue his\u002Fher suppressive antiviral therapy,\n* Patient with known lactose intolerance,\n* Patient who participated in a clinical study in the previous 3-month period,\n* Patient who is not sufficiently motivated to engage in a follow-up period of 12 months, or likely to travel or to move before the end of the study,\n* Patient with severe immunodeficiency disease requiring long term treatment (\\*) or under chemotherapy or radiotherapy or corticoid therapy,\n* Patient under listed homeopathic or phytotherapy treatment,\n* Patient using or addicted to recreational drugs.\n\n(\\*) important renal or respiratory insufficiency, transplanted or grafted patients HIV\u002FAIDS, terminal cancer.","16 Years","80 Years",{"count":60,"type":21},140,[62],"PHASE4","Herpes simplex virus (HSV) infection is very common, as most people will experience herpetic infection during their lifetime. The most common manifestation of HSV infection is sores which may appear at any age.\n\nNo specific antiviral therapy is available to totally cure herpetic infections and today, there is no treatment that allows the definitive eradication of the virus.\n\nThe 2LHERP® has been available for more than 20 years, and has received a marketing authorization in Belgium by the FAMHP. It is used as an immune regulator in the treatment of herpetic infections. Since 2LHERP® has been made available, clinical observational data collected on treated patients have shown the beneficial effect on the disappearance of herpetic recurrences.\n\nThe purpose of this placebo-controlled trial is to evaluate the efficacy of 2LHERP® on the treatment of herpetic infections in adults.",[30],"2024-10-29",{"date":67,"type":40},"2024-10-31",{"date":69,"type":40},"2020-03-10",{"date":71,"type":21},"2027-03-31",{"name":73,"class":74},"Labo'Life","INDUSTRY",6]